Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.95 -0.7%	$2.64	$0.87 ▼ $4.08	$410.70M	1.48	713,431 shs	815,258 shs
CRBP Corbus Pharmaceuticals	$9.31 +0.4%	$8.32	$4.64 ▼ $61.89	$113.43M	3.2	122,735 shs	122,153 shs
FULC Fulcrum Therapeutics	$6.83 +1.5%	$7.17	$2.32 ▼ $10.13	$364.04M	2.47	954,870 shs	1.01 million shs
RGNX REGENXBIO	$8.19 -3.8%	$8.88	$5.03 ▼ $13.48	$426.86M	1.11	559,914 shs	539,624 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	-0.67%	-7.23%	+12.60%	+56.08%	+186.41%
CRBP Corbus Pharmaceuticals	+0.43%	+0.54%	+20.13%	+19.51%	-84.35%
FULC Fulcrum Therapeutics	+1.49%	-12.55%	-1.44%	+21.53%	-26.40%
RGNX REGENXBIO	-3.76%	-8.59%	-4.99%	-21.25%	-42.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	2.3779 of 5 stars	3.6	1.0	0.0	1.1	5.0	0.0
CRBP Corbus Pharmaceuticals	4.7358 of 5 stars	4.6	3.0	4.7	3.2	2.5	0.6
FULC Fulcrum Therapeutics	2.2669 of 5 stars	3.3	3.0	0.0	2.0	2.5	0.0
RGNX REGENXBIO	4.1235 of 5 stars	3.4	1.0	4.6	2.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.10	Buy	$12.67	329.38% Upside
CRBP Corbus Pharmaceuticals	3.10	Buy	$49.38	430.34% Upside
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	10.86% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	286.14% Upside

Current Analyst Ratings Breakdown

Latest CRBP, CMPX, FULC, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$28.00
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
7/12/2025	CRBP Corbus Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	479.92	N/A	N/A	$0.91 per share	3.24
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$11.69 per share	N/A
FULC Fulcrum Therapeutics	$80M	4.62	N/A	N/A	$3.96 per share	1.72
RGNX REGENXBIO	$83.33M	4.93	N/A	N/A	$5.24 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
CRBP Corbus Pharmaceuticals	-$40.21M	-$4.22	N/A	N/A	N/A	N/A	-36.87%	-32.87%	8/5/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	N/A
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)

Latest CRBP, CMPX, FULC, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	N/A	N/A	N/A	$40.87 million	N/A
8/5/2025	Q2 2025	CRBP Corbus Pharmaceuticals	-$1.35	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/6/2025	Q1 2025	CRBP Corbus Pharmaceuticals	-$1.26	-$1.39	-$0.13	-$1.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	8.33	8.33
CRBP Corbus Pharmaceuticals	N/A	11.82	11.82
FULC Fulcrum Therapeutics	N/A	24.42	28.71
RGNX REGENXBIO	N/A	2.93	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
CRBP Corbus Pharmaceuticals	64.64%
FULC Fulcrum Therapeutics	89.83%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
CRBP Corbus Pharmaceuticals	3.60%
FULC Fulcrum Therapeutics	7.00%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CRBP Corbus Pharmaceuticals	40	12.24 million	11.80 million	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable

CRBP, CMPX, FULC, and RGNX Headlines

Recent News About These Companies

REGENXBIO Publishes Preclinical Data Highlighting RGX-202’s Potential for Duchenne Muscular Dystrophy

August 1 at 4:48 AM | insidermonkey.com

GSA Capital Partners LLP Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX)

August 1 at 3:28 AM | marketbeat.com

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

July 31 at 7:05 AM | prnewswire.com

REGENXBIO (RGNX) Expected to Announce Quarterly Earnings on Thursday

July 31 at 3:19 AM | marketbeat.com

Cerity Partners LLC Makes New $228,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)

July 29, 2025 | marketbeat.com

Analysts Set REGENXBIO Inc. (NASDAQ:RGNX) Target Price at $31.63

July 28, 2025 | americanbankingnews.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages

July 25, 2025 | marketbeat.com

REGENXBIO Inc. (RGNX): A Bull Case Theory

July 24, 2025 | insidermonkey.com

FY2028 EPS Estimates for REGENXBIO Raised by Leerink Partnrs

July 21, 2025 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company

July 18, 2025 | finance.yahoo.com

REGENXBIO Announces Publication of Preclinical Results Demonstrating ...

July 11, 2025 | morningstar.comM

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

July 10, 2025 | prnewswire.com

RGNX | REGENXBIO Inc. Annual Income Statement - MarketWatch

July 6, 2025 | marketwatch.com

Janney Montgomery Scott LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)

July 4, 2025 | marketbeat.com

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts

June 9, 2025 | benzinga.com

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

June 6, 2025 | seekingalpha.com

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

June 6, 2025 | biopharmadive.comB

RegeNXBio shares fall, despite positive new data on RGX-202

June 6, 2025 | thepharmaletter.comT

Regenxbio’s Duchenne gene therapy data positive as shares falter

June 5, 2025 | bioworld.comB

Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy

June 5, 2025 | biospace.comB

REGENXBIO updates Phase 1/2 data for Duchenne candidate

June 5, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, CMPX, FULC, and RGNX Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.95 -0.02 (-0.67%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.95 0.00 (0.00%)

As of 08/1/2025 07:22 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Corbus Pharmaceuticals NASDAQ:CRBP

$9.31 +0.04 (+0.43%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$9.34 +0.03 (+0.32%)

As of 08/1/2025 07:36 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Fulcrum Therapeutics NASDAQ:FULC

$6.83 +0.10 (+1.49%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.84 +0.00 (+0.07%)

As of 08/1/2025 07:47 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

REGENXBIO NASDAQ:RGNX

$8.19 -0.32 (-3.76%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$8.20 +0.02 (+0.18%)

As of 08/1/2025 06:31 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time